HT
Halozyme Therapeutics Inc
🇺🇸XNAS.HALOUnited StatesHealthcare
$108.23USDup +1.93 (+1.82%)ClosedDelayed1:26 AM
Price$108.23+1.93 (+1.82%)
Profile
- Healthcare
- Biotechnology
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- US40637H1095
- CUSIP
- 40637H109
Company
- Employees
- 423
- Headquarters
- San Diego, United States
- Website
- https://halozyme.com
- CEO
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Market
- Shares outstanding
- 113.5M
- Market cap
- $12.28B
Key dates
- Next earnings
- Nov 2, 2026
Highlights
- Market cap
- $12.09B
- EPS LTM
- $3.41
- P/E LTM
- 22.66
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $1.66B+41.15%up year on year
- Net income
- $413.6M-25.78%down year on year
- Gross margin
- 78.18%-3.7%down year on year
- Free cash flow
- $806.22M+49.11%up year on year
Other listings
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.